Related Experiment Video
Updated: Jun 24, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
[Pharmacotherapy in coronary artery disease]
Andreas W Schoenenberger1, Paul Erne
1Geriatrische Abklärungsstation, Universitätsklinik für Allgemeine Innere Medizin, Inselspital, Bern.
Abstract:
With the exception of anticoagulant therapy this article reviews pharmacotherapy for patients with coronary artery disease based on indications, clinical trials and current guidelines. Mechanisms of action, contraindications, and interactions are reviewed in this article. Only an appropriate use of available drugs according to guidelines permits to achieve the best relation of benefit and risk.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease IV: Preventive Measures